drugset / Trial / NCT06963814
Study of HC006 in Combination With a PD-1 Inhibitor in Patients With Advanced Solid Tumors
Non-randomizedSequentialOpen-labelTreatment
Summary
This is an open-label, multicenter Phase 1b clinical study to evaluate the safety, tolerability, pharmacokinetics, immunogenicity and preliminary efficacy of HC006 in combination with a PD-1 inhibitor in patients with advanced solid tumors. The trial is divided into two stages: dose-escalation and dose expansion. First, the dose-escalation study is completed to determine the recommended dose for subsequent extension studies, and then the dose expansion study is conducted in the proposed tumors with potential treatment benefits.
Timeline
- Start
- 2025-07-04
- Primary completion
- 2026-05-30
- Completion
- 2027-05-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | HC006 | Monoclonal antibody | — | — |
| Background | Pembrolizumab | Monoclonal antibody | — | — |
Indications
No indication recorded.